Growth kinetics and active surveillance for small renal masses

Current Opinion in Urology

Volumn 22, Issue 5, 2012, Pages 353-359

  Lane, Brian R ^a,b   Tobert, Conrad M ^b   Riedinger, Christopher B ^b  

^a SPECTRUM HEALTH   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; GIRENTUXIMAB;

ACCURACY; AREA UNDER THE CURVE; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COMORBIDITY; DISEASE SURVEILLANCE; HUMAN; INTERVENTION STUDY; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY METASTASIS; KIDNEY TUMOR; LIFE EXPECTANCY; MEDICAL RECORD REVIEW; MOLECULAR IMAGING; NOMOGRAM; OBSERVATIONAL STUDY; PARTIAL NEPHRECTOMY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME;

CELL PROLIFERATION; DISEASE MANAGEMENT; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; KIDNEY DISEASES; KIDNEY NEOPLASMS; LIFE EXPECTANCY; RETROSPECTIVE STUDIES; RISK FACTORS; WATCHFUL WAITING;

EID: 84864857715     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328355ecdf     Document Type: Review

References (47)

1. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008; 14:288-301.
2. Campbell SC, Lane BR. Malignant renal tumors. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology, 10th ed. Philadelphia: Saunders; 2011.
3. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol 2009; 182:1271-1279.
4. Lane BR, Chen H, Morrow M, et al. Increasing use of kidney sparing approaches for localized renal tumors in a community based health system: impact on renal functional outcomes. J Urol 2011; 186:1229-1235.
5. Thompson RH, Kaag M, Vickers A, et al. Contemporary use of partial nephrectomy at a tertiary care center in the United States. J Urol 2009; 181:993-997.
6. Dulabon LM, Lowrance WT, Russo P, Huang WC. Trends in renal tumor surgery delivery within the United States. Cancer 2010; 116:2316-2321.
7. Volpe A, Cadeddu JA, Cestari A, et al. Contemporary management of small renal masses. Eur Urol 2011; 60:501-515.
8. Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010; 116:3119-3126.
9. Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 2010; 28:311-317.
10. Lane BR, Babineau D, Kattan MW, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7cm or less amenable to partial nephrectomy. J Urol 2007; 178:429-434. (Pubitemid 47030487)
11. Remzi M, Ozsoy M, Klingler HC, et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4cm or less in diameter. J Urol 2006; 176:896-899. (Pubitemid 44142601)
12. Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 2003; 170 (6 Pt 1): 2217-2220. (Pubitemid 37413960)
13. Raj GV, Thompson RH, Leibovich BC, et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 2008; 179:2146-2151; discussion 2151.
14. Kutikov A, Smaldone MC, Egleston BL, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol 2011; 60:241-248.
15. Mason RJ, Abdolell M, Rendon RA. Tumour location as a predictor of benign disease in the management of renal masses. Can Urol Assoc J 2010; 4:414-417.
16. Barrisford GW, Singer EA, Rosner IL, et al. Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol 2011; 2011:658767.
17. Walther MM, Choyke PL, Glenn G, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 1999; 161:1475-1479. (Pubitemid 29420799)
18. Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol 2009; 181:1020-1027; discussion 1027.
19. Bosniak MA. Observation of small incidentally detected renal masses. Semin Urol Oncol 1995; 13:267-272.
20. Fujimoto N, Sugita A, Terasawa Y, Kato M. Observations on the growth rate of renal cell carcinoma. Int J Urol 1995; 2:71-76.
21. Rendon RA, Stanietzky N, Panzarella T, et al. The natural history of small renal masses. J Urol 2000; 164:1143-1147.
22. Oda T, Miyao N, Takahashi A, et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol 2001; 8:473-477. (Pubitemid 32953817)
23. Kassouf W, Aprikian AG, Laplante M, Tanguay S. Natural history of renal masses followed expectantly. J Urol 2004; 171:111-113; discussion 113. (Pubitemid 37549102)
24. Volpe A, Panzarella T, Rendon RA, et al. The natural history of incidentally detected small renal masses. Cancer 2004; 100:738-745. (Pubitemid 38176851)
25. Wehle MJ, Thiel DD, Petrou SP, et al. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology 2004; 64:49-52. (Pubitemid 38887577)
26. Kato M, Suzuki T, Suzuki Y, et al. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol 2004; 172:863-866. (Pubitemid 39096408)
27. Sowery RD, Siemens DR. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can J Urol 2004; 11:2407-2410.
28. Lamb GW, Bromwich EJ, Vasey P, Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy - natural history, complications, and outcome. Urology 2004; 64:909-913. (Pubitemid 39469504)
29. Chawla SN, Crispen PL, Hanlon AL, et al. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006; 175:425-431. (Pubitemid 43067318)
30. Kouba E, Smith A, McRackan D, et al. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J Urol 2007; 177:466-470; discussion 470. (Pubitemid 46054008)
31. AbouYoussif T, Kassouf W, Steinberg J, et al. Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer 2007; 110:1010-1014. (Pubitemid 47312866)
32. Siu W, Hafez KS, Johnston WK 3rd, Wolf JS Jr. Growth rates of renal cell carcinoma and oncocytoma under surveillance are similar. Urol Oncol 2007; 25:115-119. (Pubitemid 46349757)
33. Matsuzaki M, Kawano Y, Morikawa H, et al. Conservative management of small renal tumors. Hinyokika Kiyo 2007; 53:207-211.
34. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol 2008; 180:505-508; discussion 508-509.
35. Crispen PL, Viterbo R, Boorjian SA, et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 2009; 115:2844-2852.
36. Rosales JC, Haramis G, Moreno J, et al. Active surveillance for renal cortical neoplasms. J Urol 2010; 183:1698-1702.
37. Lane BR, Samplaski MK, Herts BR, et al. Renal mass biopsy - a renaissance? J Urol 2008; 179:20-27.
38. Samplaski MK, Zhou M, Lane BR, et al. Renal mass sampling: an enlightened perspective. Int J Urol 2011; 18:5-19.
39. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007; 25:4757-4764. (Pubitemid 350086478)
40. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007; 8:304-310. (Pubitemid 46464522)
41. Uzzo RG, Yu J, Russo P, et al. Safety and tolerability of the novel positron emission tomography (PET) molecular imaging tracer 124Igirentuximab in the diagnosis of clear cell renal cell carcinoma. Abstract #138, presented at Society of Urologic Oncology Meeting; December 2011.
42. Yamaguchi Y, Simmons MN, Campbell SC. Small renal masses: risk prediction and contemporary management. Hematol Oncol Clin North Am 2011; 25:717-736.
43. Graversen JA, Mues AC, Perez-Lanzac de Lorca A, Landman J. Active surveillance of renal cortical neoplasms: a contemporary review. Postgrad Med 2011; 123:105-113.
44. Smaldone MC, Kutikov A, Egleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 2012; 118:997-1006.
45. Mason RJ, Abdolell M, Trottier G, et al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol 2011; 59:863-867.
46. Jewett MA, Mattar K, Basiuk J, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 2011; 60:39-44.
47. Mucksavage P, Ramchandani P, Malkowicz SB, Guzzo TJ. Is ultrasound imaging inferior to computed tomography or magnetic resonance imaging in evaluating renal mass size? Urology 2012; 79:28-31.